Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study involves the experimental drug bazedoxifene acetate/conjugated estrogens (also
called BZA/CE). This drug is not approved by the Food and Drug Administration (FDA).
About 24 subjects will take part in this study. Each subject's participation in this study
will last for about 10 weeks. During this study, each subject will receive 3 different types
of BZA/CE tablets plus an oral solution containing only BZA. The purpose of this study is to
learn how the tablet dosage forms dissolve and are absorbed by the body compared to the BZA
oral solution. In addition, information will also be learned about the safety and
tolerability of these dosage forms given to healthy postmenopausal women.